$AZN-GB News
Last published 1mo ago
- 1mo agoNVSNVOAZN-GBGSK+3Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar dealsCNBCWestern biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
- 3mo agoAZN-GBBMYAstraZeneca may buck a decade of pharma strategy to buy U.S. scaleCNBCReports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.
- 4mo agoAZN-GBALNYXBIAstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?CNBCFor years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
- 4mo agoAZN-GBAstraZeneca stock dives 9% after heart drug trial misses targetCNBC
- 7mo agoAZN-GBMRKLLYTrump policies, China's biotech boom are ending Europe's pharma powerhouse eraCNBCCompanies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and uneven reimbursement policies.
- 7mo ago.FTSEAZN-GBROG-CHSAN-FRAstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failedCNBCThe experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
- 9mo agoORCLMSFT.SPX.IXIC+9CNBC Daily Open: U.S. markets rise on tech rebound, while 'Takaichi trade' lifts Japanese stocksCNBCU.S. markets closed higher overnight as Big Tech stocks mostly rebounded, with Oracle jumping 9.6% and Microsoft advancing 3.1%.
- 9mo agoAZN-GBZE821-CNFrom PopMart to JD.com: Britain and China rush to forge business deals as diplomatic thaw takes holdCNBCChinese firms moved to pledge hundreds of millions of investment in the U.K. as Starmer's visit to China spurred a flurry of business deals and money flows.
- 10mo agoLLYABVX-FR.STOXXFRES-GB+3A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last yearCNBCEurope's best performing stock in 2025, Abivax, could be snapped up any day now, analysts say.
- 11mo agoLLYROG-CHAZN-GBAMGN+3Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, LillyCNBCGrowing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry.
- 1y agoMRKPFEAZN-GBMerck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hitCNBCMerck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of tariffs."
- 1y agoAZN-GBAZNPFETrump reaches deal with AstraZeneca to lower U.S. drug pricesCNBCTrump announced the agreement with AstraZeneca on Friday, after striking a similar deal with Pfizer late last month.
- 1y agoNVOLLYAZN-GBPFE+4A world on weight loss drugs: How GLP-1s are reshaping the economyCNBCAs GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for both health outcomes and the economy.
- 1y agoAZN-GBAZNHealthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressureCNBCAstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.
- 1y agoMRKSNYAZN-GBPFE+2FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZenecaCNBCMerck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
- 1y agoAZN-GBBritish pharma giant AstraZeneca to invest $2.5 billion in new China hubCNBCBritish pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China.
- 1y agoAZN-GBAZNHealthy Returns: AstraZeneca expands U.S. investment plan on confidence in economyCNBCAstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to purchase Summa Health for $485 million.
- 2y agoNVDAJPMMSFTAZN-GB+9Cerebras IPO has 'too much hair' as AI chipmaker tries to sell Wall Street on Nvidia alternativeCNBCCerebras is playing in a huge market with insatiable investor demand, but its IPO prospectus is littered with red flags that complicate a potential debut.
- 2y agoAZN-GBAstraZeneca shares fall 5% on disappointing lung cancer drug trial resultsCNBCAstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.
- 2y agoMRKAZN-GBJNJBMY+2Healthy Returns: The first round of Medicare drug price negotiations is nearing an endCNBCThe first round of Biden's Medicare drug price negotiations is nearly finished. Meanwhile, Abridge, Epic and Mayo Clinic are bringing AI tools to nurses.
- 2y agoAZN-GBPFEMRKMRNA+3Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins bigCNBCDrugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.
- 2y agoAZN-GBBMYLLYNVS+4This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&ACNBCTargeted radiopharmaceuticals, which deliver radiation directly into tumors, has caught the eye of big pharma.
- 2y agoNOVO.B-DKAZN-GBLLYAZN+2AstraZeneca targets $80 billion in total revenue by 2030 with release of 20 new medicinesCNBCPharmaceutical company AstraZeneca is planning to increase its total revenue by 75% and release 20 new medicines by 2030, including cancer treatments.
- 2y agoAZN-GBHealthy Returns: Drugmakers are capping inhaler prices at $35 in a win for some patientsCNBCThree drugmakers are capping out-of-pocket costs for their inhalers. Meanwhile, many digital diabetes management tools aren't all they're cracked up to be.
- 2y agoZMWMTDALTMUS+6AI might be reading your Slack messages: 'A lot of this becomes thought crime'CNBCAware uses AI to analyze companies' employee messages across Slack, Microsoft Teams, Zoom and other communications services.
- 2y agoVKTXTERNundefinedNOVO.B-DK+8The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming spaceCNBCWall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.
- 2y agoPFEADCTJNJAMAM+4Biotech and pharma companies are betting on a promising class of cancer drugs to drive growthCNBCThe JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
- 2y agoMRKJNJBMYAZN-GB+2Biden administration's Medicare drug price negotiations will face major tests in 2024CNBCNext year could set the precedent for the Inflation Reduction Act's controversial talks, which could affect dozens of medications by the end of the decade.
- 2y agoLLYNOVO.B-DKPFEAMGN+6Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharmaCNBCWall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.
- 2y agoPFENOVO.B-DKLLYAMGN+4The weight loss drug boom isn't over yet — here's what to expect in the year aheadCNBC2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.
- 2y agoSAN-FRAZN-GBCDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortageCNBCThe CDC's move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise in some parts of the country.
- 3y agoBMYJNJMRKAZN-GB+5Drugmakers opt in to Medicare drug price negotiations – here's what happens nextCNBCThe lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.
- 3y agoMRKJNJBMYAZN-GB+1Federal judge declines to block Medicare price negotiationsCNBCJudge Michael Newman of the Southern District of Ohio issued a ruling denying a preliminary injunction sought by the Chamber of Commerce.
- 3y agoAZN-GBBMYJNJMRKAstraZeneca, Boehringer Ingelheim to participate in Medicare drug price negotiationsCNBCAstraZeneca, Boehringer Ingelheim and other drugmakers have filed at least eight lawsuits seeking to declare the Medicare price talks unconstitutional.
- 3y agoAZN-GBURBNFLDOW+12Stocks making the biggest moves in premarket trading: AstraZeneca, Paramount, Nike and moreCNBCThese are the stocks posting the largest moves in early trading.
- 3y agoPFESAN-FRAZN-GBCDC advisors recommend Pfizer maternal RSV vaccine to protect infantsCNBCCDC Director Mandy Cohen still needs to sign off on that recommendation before mothers can receive Pfizer's shot to protect their infants from RSV.
- 3y agoPDDCHTRAZN-GBW+5Stocks making the biggest moves premarket: AstraZeneca, Wayfair, Alibaba and moreCNBCThese are the stocks posting the largest moves before the bell.
- 3y agoBABATWNKMRNAIMTX+13Stocks making the biggest moves midday: Tesla, Qualcomm, Meta, Moderna and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 3y agoBMYMRKMRNAAZN-GB+1Judge withdraws from Medicare drug price case after stock ownership is revealedCNBCJudge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.
- 3y agoAZN-GBMRKBMYJNJ+3Medicare drug price negotiations may have a muted impact on drugmakers in the near termCNBCMany of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.
- 3y agoPFESAN-FRAZN-GBFDA approves Pfizer maternal RSV vaccine for infantsCNBCPfizer hopes that its respiratory syncytial virus vaccine will be available to the public by the end of October or the beginning of November.
- 3y agoPFEAZN-GBAMGNJNJ+4These 10 medications are likely targets for Medicare price negotiations this fallCNBCIt's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.
- 3y agoINTCROKUBIIBRETA+13Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and moreCNBCThese are the stocks posting the largest moves in premarket trading.
- 3y agoNOVO.B-DKSAN-FRAZN-GBLLYUK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risksCNBCThe probe into potentially life-threatening side effects comes as the drugs skyrocket in popularity in the U.S. and draw heightened investor interest.
- 3y agoAZN-GBSAN-FRSanofi expects infant RSV shot to roll out before respiratory virus season this fallCNBCSanofi said it is working with a CDC panel to include Beyfortus on the childhood immunization schedule and the Vaccines for Children Program.
- 3y agoSAN-FRAZN-GBFDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSVCNBC
- 3y agoMRNAPFEAZN-GBNOVO.B-DK+3Moderna strikes deal to develop mRNA drugs in ChinaCNBCThe deal is the biotech company's first agreement with China after the Asian nation repeatedly refused to accept mRNA vaccines from U.S.-based manufacturers.
- 3y agoRIG.N-CHCOINUPSRIVN+6Stocks making the biggest moves in the premarket: Rivian, UPS, Coinbase and moreCNBCThese are the stocks posting the largest moves premarket.
- 3y agoRIVNFSRLCIDXPEV+11Stocks making the biggest moves midday: Tesla, Rivian, XPeng and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 3y agoTSLARIVNFSRLCID+15Stocks making the biggest moves in the premarket: Tesla, Apple, AstraZeneca and moreCNBCThese are the stocks posting the largest moves in premarket trading.